Arformoterol Tartrate NDC 62756-277

NDC codes

FDA NDC Directory

Product NDC (as listed)62756-277Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62756-0277Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62756-277-02	62756027702	6 POUCH in 1 CARTON (62756-277-02) / 5 VIAL, SINGLE-DOSE in 1 POUCH / 2 mL in 1 VIAL, SINGLE-DOSEMarketed from May 28, 2022
62756-277-03	62756027703	12 POUCH in 1 CARTON (62756-277-03) / 5 VIAL, SINGLE-DOSE in 1 POUCH / 2 mL in 1 VIAL, SINGLE-DOSEMarketed from May 28, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Arformoterol Tartrate
Generic name (nonproprietary): arformoterol tartrate
Active ingredients: Arformoterol tartrate — 15 ug/2mL
Dosage form: Solution
Route: Respiratory (Inhalation)
Labeler: Sun Pharmaceutical Industries, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215385
Marketing start: May 28, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Adrenergic beta2-Agonists (Mechanism)
Identifiers: Product ID 62756-277_5314ef39-4fbf-4a1a-a101-efcc1e505fdfSPL ID 5314ef39-4fbf-4a1a-a101-efcc1e505fdfSPL set ID f1005878-0c48-4b9a-843e-b6cf6b8bb251RxCUI 668956UNII 5P8VJ2I235
Pharmacologic class: beta2-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N462756027702 followed by a unit qualifier and the quantity

Package 62756-0277-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 14, 2026.

Indications (excerpt from the label)

Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. (1.1) Important limitations of use: Arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2, 5.2) Arformoterol tartrate inhalation solution is not indicated to treat asthma. (1.2) 1.1 Maintenance Treatment of COPD Arformoterol tartrate inhalation solution is indicated for the long-…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215385

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215385
Product	Strength	Form · route	Labeler	Product NDC
Arformoterol Tartrate	Arformoterol tartrate 15 ug/2mL	SolutionRespiratory (Inhalation)	American Health Packaging	60687-770